[1] 胡大一,马长生,心脏病学实践2012-规范化治疗[M].北京:人民卫生出版社,2012: 298-301.
[2] Wang X, Xi WC, Wang F.The beneficial effects of intracoronary autologous bone marrow stem cell transfer as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction. Biotechnol Lett.2014;36(11):2163-2168.
[3] Brickwedel J, Gulbins H, Reichenspurner H. Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease. Interact Cardiovasc Thorac Surg. 2014;18(1):61-66.
[4] Poglajen G, Vrtovec B.Stem cell therapy for chronic heart failure. Curr Opin Cardiol.2015;30(3):301-310.
[5] Agathopoulos S, Kolettis TM.Novel strategies for cardiac repair post-myocardial infarction.Curr Pharm Des.2014;20(12): 1925-1929.
[6] Sanganalmath SK, Bolli R.Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.Circ Res.2013;113(6): 810-834.
[7] Bryant SJ, Cuy JL, Hauch KD, et al.Photo-patterning of porous hydrogels for tissue engineering. Biomaterials.2007;28(19): 2978-2986.
[8] Kang HJ, Lee HY, Na SH, et al.Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation.2006;114(1 Suppl): 145-151.
[9] Guarita-Souza LC, Francisco JC, Simeoni R, et al.Benefit of stem cells and skeletal myoblast cells in dilated cardiomyopathies.World J Cardiol.2011; 26;3(3):93-97.
[10] Fujita T,Sakaguchi T,Miyagawa S,et al.Clinical impact of combined transplantation of autologous skeletal myoblasts and bone marrow mononuclear cells in patients with severely deteriorated ischemic cardiomyopathy.Surg Today. 2011;41(8): 1029-1036.
[11] Povsic TJ, O'Connor CM, Henry T,et al. A double-blind,randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J. 2011;162(4): 654-662.
[12] Irintchev A, Zweyer M, Wernig A.Cellular and molecular reactions in mouse muscles after myoblast implantation. J Neurocytol. 1995;24(4): 319-331.
[13] Mouquet F,Lemesle G,Delhaye C,et al. The presence of apoptotic bone marrow cells impairs the efficacy of cardiac cell therapy.Cell Transplant.2011;20(7):1087-1097.
[14] Pouzet B, Vilquin JT, Hagège AA,et al. Intramyocardial transplantation of autologous myoblasts: Can tissue processing be optimized?. Circulation.2000;102(19): 210-215.
[15] Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases(ROCKs):potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011,32(3): 167-173.
[16] Dong M, Yan BP, Yu CM. Current status of rho-associated kinase (ROCKs) in coronary atherosclerosis and vasospasm. Cardiovasc Hematol Agents MedChem.2009; 7(4):322-330.
[17] Shi J, Wei L. Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.J Cardiovasc Pharmacol. 2013 ;62(4):341-354.
[18] Ho TJ, Huang CC, Huang CY, et al. Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats. Eur J Appl Physiol.2012;112(8):2943-2955.
[19] Surma M, Wei L, Shi J.Rho kinase as a therapeutic target in cardiovascular disease.Future Cardiol. 2011;7(5):657-671.
[20] Hirooka Y, Shimokawa H.Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs. 2005;5(1):31-39.
[21] Fukui S, Fukumoto Y, Suzuki J, Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.J Cardiovasc Pharmacol. 2008;51(3):317-326.
[22] Jiang ZH,Zhang TT, Zhang JF,et al.Protective effects of fasudil hydrochloride post-conditioning on acute myocardial ischemia/ reperfusion injury in rats. Cardiol J. 2013;20(2):197-202.
[23] Sun XZ, Tian XY, Wang DW, Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Eur Rev Med Pharmacol Sci. 2014;18(7):959-964.
[24] Dong M,Yan BP,Liao JK,et al.Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.Drug Discovery Today.2010;15(15): 622-629.
[25] Geng YJ.Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure.Ann NY Acad Sci. 2003;1010:687-697.
[26] Hale SL, Dai W, Dow JS, et al. Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes:a quantitative assessment.Life Sci.2008;83 (13 /14):511-515.
[27] Marchant DJ,Boyd JH,Lin DC,et al.Inflammation in myocardial diseases. Circ Res.2012;110(1):126-144.
[28] González A,Ravassa S,Beaumont J,et al. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58(18):1833-1843.
[29] 陈科奇,董少红,罗林杰.重组人促红细胞生成素联合骨骼肌卫星细胞移植对兔急性心肌梗死的影响[J].中国组织工程研究与临床康复, 2008,12(29):5639-5644.
[30] Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction.Circulation.1997;95(2):320-323
[31] Jiang ZH, Zhang TT, Zhang JF. Protective effects of fasudil hydrochloride post-conditioning on acute myocardial ischemia/reperfusion injury in rats. Cardiol J. 2013;20(2):197-202.
[32] Del Re DP,Miyamoto S, Brown JH,et al.RhoA/Rho kinase upregulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis.J Biol Chem.2007;282(11): 8069-8078. |